Shorter exclusivity for later-in-class drugs without added benefit
The fifth PD-1 antibody that is no better than the first should not get the same market protection as the first. Exclusivity would shrink for copies that add nothing.
The mirror image of value-based extension: for the third and subsequent entrants in a mechanistic class, regulatory data exclusivity is reduced (for example from eight to four years) unless a head-to-head trial demonstrates superiority or a clinically meaningful advantage (toxicity, route, population) graded on a public scale such as ESMO-MCBS. This does not block approval, which remains safety- and efficacy-based, but changes the return profile of me-too development so that capital moves to unmet needs. Capital diverted from copies is the point; the risk is reduced price competition within class, which can be offset by an abbreviated pathway for biosimilar-like entrants.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
Pages like this
not linked directly; found by shared links- IdeaExtra exclusivity for sponsors who run treatment-duration and de-escalation trials
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Nivolumab, Pembrolizumab.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Prices and value, Nivolumab, PD-1, Pembrolizumab.
- IdeaPublicly funded dose-reduction trials of expensive approved drugs
Shares Incentives reward me-too drugs and marginal gains, Prices and value, Nivolumab, Pembrolizumab.
- IdeaAutomatic price cuts when a cancer drug's approved indications and volumes expand
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Prices and value, Nivolumab, PD-1, Pembrolizumab.
- IdeaLaunch prices indexed to the ESMO benefit scale, revisited when survival matures
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaRestore weight-based dosing and vial sharing for immunotherapy in the label
Shares Prices and value, Nivolumab, Pembrolizumab.